Keytruda® (pembrolizumab) – New indication
November 13, 2020 - Merck announced the FDA approval of Keytruda (pembrolizumab), in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS ≥ 10) as determined by an FDA-approved test.
Top